EGFR and non-small cell lung carcinoma: Gefitinib or erlotinib combined with chemotherapy has been recommended as a first-line treatment for stage IV EGFR mutant NSCLC (PS = 0–1) in the NSCLC guidelines of Chinese Society of Clinical Oncology in 2017.